The official blog of Bivium Biosciences. Stay up on the latest news in the neurodegeneration space.

Follow the company

No news or media at this time

A $354M financing into a CNS program isn’t just a headline—it’s a signal. After years of hesitation, serious capital is re-engaging in neurology with a sharper lens on mechanism, patient selection, and clinical path.

Phillipe Deschamps, CEO & President

Follow

Phil Deschamps, CEO & President

Phil is the CEO of Bivium Biosciences, leading development of neuroprotective therapies for neurodegenerative diseases, driven by personal loss and a commitment to advancing transformative, disease-modifying treatments for patients.

Follow Phil

The official blog of Bivium Biosciences. Stay up on the latest news in the neurodegeneration space.

Follow the company

Fill in your basic details, and one of our experts will get in touch with you shortly.